Immunity and cancer face to face. Highlights of medical achievements in 2018

The Nobel Society of the Karolinska Institute in Sweden, October 1, highlighted the role played by James Allison and Japanese Tasuko Hongo in stimulating the immune system to fight cancer, which earned them the Nobel Prize of Medicine.

The professor at the MD Anderson Cancer Institute of the University of Texas, Allison, discovered a protein that inhibits the immune system, while Hungo, a professor at Kyoto University, discovered a second protein in the cells immune system that also disrupts the immune system, but with a different mechanism.

The two scientists concluded that immune cells could be used to attack tumors if proteins were stopped.

While the Nobel laureate of the planet has highlighted their efforts to release cancer immunity, many other research papers have been published by research centers in 2018 and have the same purpose.

One of these studies concerns the success of British researchers in developing a cancer treatment using a genetically modified virus to produce proteins that strengthen the immune system to attack cancer cells and "misleading" fibroblasts.

The researchers used a virus called Enade notucirev, which has been modified: cancer cells help produce BTEs that activate immune cells to kill defective cells and their badociated fibroblasts.

Cancer Research Journal has published an article on this result, which has been described as the first of its kind to provide a way to kill cancer cells and fibroids that protect them at the same time, without harming the rest of the body.

Another study focused on the activation of the immune system against cancer, but in a different way, a hydroperopterin, also known as "BH4".

In 2013, researchers at the Boston Hospital discovered that the protein was responsible for the pain and were preparing to work on a mechanism to discourage its production in the body in order to prevent the development of acute pain to chronic in millions of patients, studies of the Institute of Molecular Biotechnology (IMBA) of others may be more useful because they act as immune regulators in the body, resulting in levels of в # <в # < high activity in immune cells, called "T-cells", which are reflected positively on the blocking of cancerous tumors.

The research team of the Austrian Institute collaborated with the Boston Children's Hospital research team in this direction and published an article in the journal Nature in which it was possible to block cancer cells by increasing BH4 protein levels, which boosted the immune response.

The researchers promised to integrate this effort into clinical trials that give a better idea of ​​the immune system's ability to win the battle of cancer. Is 2019 news that millions of people around the world are waiting?